About inmed pharmaceuticals - INM
InMed Pharmaceuticals, Inc. engages in developing small molecule drug candidates targeting the CB1/CB2 receptors. It operates through the InMed Pharma and BayMedica Commercial segments. The InMed Pharma segment focuses on research and development. The BayMedica Commercial segment refers to manufacturing technologies to produce and commercialize bulk cannabinoids for sale as ingredients in the health and wellness industry. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
INM At a Glance
InMed Pharmaceuticals, Inc.
885 West Georgia Street
Vancouver, British Columbia V6C 3E8
| Phone | 1-604-669-7207 | Revenue | 4.94M | |
| Industry | Pharmaceuticals: Major | Net Income | -8,162,133.00 | |
| Sector | Health Technology | 2025 Sales Growth | 7.502% | |
| Fiscal Year-end | 06 / 2026 | Employees | 13 | |
| View SEC Filings |
INM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.642 |
| Price to Book Ratio | 0.484 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.976 |
| Enterprise Value to Sales | -1.458 |
| Total Debt to Enterprise Value | -0.103 |
INM Efficiency
| Revenue/Employee | 380,202.538 |
| Income Per Employee | -627,856.385 |
| Receivables Turnover | 10.627 |
| Total Asset Turnover | 0.361 |
INM Liquidity
| Current Ratio | 6.994 |
| Quick Ratio | 6.471 |
| Cash Ratio | 6.044 |
INM Profitability
| Gross Margin | 23.709 |
| Operating Margin | -160.198 |
| Pretax Margin | -165.137 |
| Net Margin | -165.137 |
| Return on Assets | -59.571 |
| Return on Equity | -72.102 |
| Return on Total Capital | -57.578 |
| Return on Invested Capital | -69.196 |
INM Capital Structure
| Total Debt to Total Equity | 5.518 |
| Total Debt to Total Capital | 5.229 |
| Total Debt to Total Assets | 4.758 |
| Long-Term Debt to Equity | 2.276 |
| Long-Term Debt to Total Capital | 2.157 |